Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)
Eric L. Simpson, Seth Forman, Jonathan I. Silverberg, et al.
Journal of the American Academy of Dermatology (2021) Vol. 85, Iss. 1, pp. 62-70
Open Access | Times Cited: 110

Showing 26-50 of 110 citing articles:

JAK/STAT signaling in diabetic kidney disease
Yingjun Liu, Wenkuan Wang, Jintao Zhang, et al.
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access | Times Cited: 25
Systemic Immunomodulatory Treatments for Atopic Dermatitis
Aaron M. Drucker, Megan Lam, David Prieto‐Merino, et al.
JAMA Dermatology (2024) Vol. 160, Iss. 9, pp. 936-936
Closed Access | Times Cited: 12
Short-Term Cardiovascular Complications in Dermatology Patients Receiving JAK-STAT Inhibitors
Patrick A. Ireland, Nicholas Jansson, Sascha Spencer, et al.
JAMA Dermatology (2024) Vol. 160, Iss. 3, pp. 281-281
Closed Access | Times Cited: 10
Molecular and cellular mechanisms of itch and pain in atopic dermatitis and implications for novel therapeutics
Shawn G. Kwatra, L. Misery, Claire Clibborn, et al.
Clinical & Translational Immunology (2022) Vol. 11, Iss. 5
Open Access | Times Cited: 37
A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19
Thomas Bieber, Eugen Feist, Alan D. Irvine, et al.
Advances in Therapy (2022) Vol. 39, Iss. 11, pp. 4910-4960
Open Access | Times Cited: 37
Application of Baricitinib in Dermatology
Jingya Zhang, Fei Qi, Jie Dong, et al.
Journal of Inflammation Research (2022) Vol. Volume 15, pp. 1935-1941
Open Access | Times Cited: 31
Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials
Thomas Bieber, Norito Katoh, Eric L. Simpson, et al.
Journal of Dermatological Treatment (2022) Vol. 34, Iss. 1
Open Access | Times Cited: 31
Spesolimab, an anti‐interleukin‐36 receptor antibody, in patients with moderate‐to‐severe atopic dermatitis: Results from a multicentre, randomized, double‐blind, placebo‐controlled, phase IIa study
Robert Bissonnette, William Abramovits, Étienne Saint‐Cyr Proulx, et al.
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 37, Iss. 3, pp. 549-557
Open Access | Times Cited: 30
Biologic Versus Small Molecule Therapy for Treating Moderate to Severe Atopic Dermatitis: Clinical Considerations
Sneha Butala, Leslie Castelo‐Soccio, Rishi Seshadri, et al.
The Journal of Allergy and Clinical Immunology In Practice (2023) Vol. 11, Iss. 5, pp. 1361-1373
Open Access | Times Cited: 21
Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis
Barbara Rewerska, Lawrence Sher, Sady Alpizar, et al.
Journal of Allergy and Clinical Immunology Global (2023) Vol. 3, Iss. 1, pp. 100195-100195
Open Access | Times Cited: 19
IL‐13, periostin and dipeptidyl‐peptidase‐4 reveal endotype‐phenotype associations in atopic dermatitis
Laura Maintz, Thomas Welchowski, Nadine Herrmann, et al.
Allergy (2023) Vol. 78, Iss. 6, pp. 1554-1569
Open Access | Times Cited: 18
The Use of JAK/STAT Inhibitors in Chronic Inflammatory Disorders
Giuseppina Caiazzo, Anna Caiazzo, Maddalena Napolitano, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 8, pp. 2865-2865
Open Access | Times Cited: 18
Major adverse cardiovascular events in patients with atopic dermatitis treated with oral Janus kinase inhibitors: a systematic review and meta-analysis
C. Ertus, Lucie‐Marie Scailteux, Alain Lescoat, et al.
British Journal of Dermatology (2023) Vol. 189, Iss. 4, pp. 368-380
Closed Access | Times Cited: 18
Infection risk with JAK inhibitors in dermatoses: a meta‐analysis
Patrick A. Ireland, Matthew J Verheyden, Nicholas Jansson, et al.
International Journal of Dermatology (2024)
Open Access | Times Cited: 7
Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials
Brett King, Catherine Maari, Edward Lain, et al.
American Journal of Clinical Dermatology (2021) Vol. 22, Iss. 3, pp. 395-405
Open Access | Times Cited: 38
Baricitinib: The First Jak Inhibitor Approved in Europe for the Treatment of Moderate to Severe Atopic Dermatitis in Adult Patients
Giulia Radi, Oriana Simonetti, Giulio Rizzetto, et al.
Healthcare (2021) Vol. 9, Iss. 11, pp. 1575-1575
Open Access | Times Cited: 33
Impact of a Decade of Research Into Atopic Dermatitis
Peter D. Arkwright, Jennifer J. Koplin
The Journal of Allergy and Clinical Immunology In Practice (2022) Vol. 11, Iss. 1, pp. 63-71
Open Access | Times Cited: 27
Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
Sheridan M. Hoy
American Journal of Clinical Dermatology (2022) Vol. 23, Iss. 3, pp. 409-420
Open Access | Times Cited: 24
Comparative Efficacy and Safety of Monoclonal Antibodies and Janus Kinase Inhibitors in Moderate-to-severe Atopic Dermatitis: A Systematic Review and Meta-analysis
Farnam Barati Sedeh, Mattias A. S. Henning, Gregor B. E. Jemec, et al.
Acta Dermato Venereologica (2022) Vol. 102, pp. adv00764-adv00764
Open Access | Times Cited: 23
Emerging Systemic Treatments for Atopic Dermatitis
Silvia Ferrucci, Simona Tavecchio, Angelo Valerio Marzano, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 5, pp. 1071-1081
Open Access | Times Cited: 15
Efficacy and safety of rademikibart (CBP-201), a next-generation mAb targeting IL-4Rα, in adults with moderate to severe atopic dermatitis: A phase 2 randomized trial (CBP-201-WW001)
Jonathan I. Silverberg, Bruce Strober, Brian A. Feinstein, et al.
Journal of Allergy and Clinical Immunology (2023) Vol. 153, Iss. 4, pp. 1040-1049.e12
Closed Access | Times Cited: 13
Modern treatment methods in atopic dermatitis - literature overview
Martyna Borowska-Łygan, J E Tomaszewski, Wojciech Urban, et al.
Journal of Education Health and Sport (2025) Vol. 77, pp. 56830-56830
Open Access
Efficacy of Janus kinase inhibitors in immune-mediated inflammatory diseases—a systematic literature review informing the 2024 update of an international expert consensus statement
Victoria Konzett, Josef S Smolen, Peter Nash, et al.
Annals of the Rheumatic Diseases (2025)
Open Access
Baricitinib in the Treatment of Severe Atopic Dermatitis Resistant to Cyclosporine: A Case Report Involving Two Cases
Abhishek De, Sk Shahriar Ahmed, Disha Chakraborty, et al.
Cureus (2025)
Open Access
Insights into atopic dermatitis pathogenesis lead to newly approved systemic therapies
Anna M. Trier, Brian Kim
British Journal of Dermatology (2022) Vol. 188, Iss. 6, pp. 698-708
Open Access | Times Cited: 19

Scroll to top